{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T22:59:06Z","timestamp":1780786746150,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004480","name":"Shanxi Province Natural Science Foundation","doi-asserted-by":"publisher","award":["202303021211229"],"award-info":[{"award-number":["202303021211229"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jgar.2025.09.005","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T06:01:19Z","timestamp":1758607279000},"page":"107-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Population pharmacokinetics of imipenem in solid tumor patients with infections: A real-world study"],"prefix":"10.1016","volume":"45","author":[{"given":"Tingting","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6836-6695","authenticated-orcid":false,"given":"Zhiying","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.09.005_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jgar.2025.09.005_bib0002","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/pathogens11060679","article-title":"Pseudomonas aeruginosa infections in cancer patients","volume":"11","author":"Paprocka","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.jgar.2025.09.005_bib0003","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/21505594.2016.1141161","article-title":"Bloodstream infections in patients with solid tumors","volume":"7","author":"Gudiol","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.jgar.2025.09.005_bib0004","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jinf.2014.05.018","article-title":"Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours","volume":"69","author":"Marin","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2025.09.005_bib0005","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13318-020-00643-3","article-title":"Pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with extracorporeal membrane oxygenation","volume":"45","author":"Jaruratanasirikul","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jgar.2025.09.005_bib0006","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/ajhp\/zxab012","article-title":"Imipenem\/cilastatin\/relebactam: A new carbapenem \u03b2-lactamase inhibitor combination","volume":"78","author":"Mansour","year":"2021","journal-title":"Am J Health-System Pharm"},{"key":"10.1016\/j.jgar.2025.09.005_bib0007","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02235-21","article-title":"In vitro antibacterial activity of imipenem\/relebactam against clinical isolates in Japan","volume":"10","author":"Kurihara","year":"2022","journal-title":"Microbiology Spectrum"},{"key":"10.1016\/j.jgar.2025.09.005_bib0008","article-title":"Population pharmacokinetics and pharmacodynamics of imipenem in neutropenic adult patients","volume":"53","author":"Lafaurie","year":"2023","journal-title":"Infect Dis Now"},{"key":"10.1016\/j.jgar.2025.09.005_bib0009","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/bcp.12435","article-title":"Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens","volume":"78","author":"Couffignal","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2025.09.005_bib0010","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/pharmaceutics9030036","article-title":"Augmented renal clearance in critical illness: an important consideration in drug dosing","volume":"9","author":"Mahmoud","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jgar.2025.09.005_bib0011","article-title":"Antimicrobial dose reduction in continuous renal ReplacementTherapy: myth or real need? A practical approach for guiding dose optimization of novel antibiotics","volume":"60","author":"M","year":"2021","journal-title":"Clin Pharmacokinetics"},{"key":"10.1016\/j.jgar.2025.09.005_bib0012","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.2147\/IDR.S373348","article-title":"Population-based pharmacokinetics and dose optimization of Imipenem in Vietnamese critically-ill patients","volume":"15","author":"Dinh","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2025.09.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2012.4","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jgar.2025.09.005_bib0014","article-title":"Prediction-corrected visual predictive checks fordiagnosing nonlinear mixed-effects models","volume":"13","author":"M","year":"2011","journal-title":"The AAPS Journal"},{"key":"10.1016\/j.jgar.2025.09.005_bib0015","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00134-006-0470-5","article-title":"Pharmacokinetic\/pharmacodynamic analysis of vancomycin in ICU patients","volume":"33","author":"del Mar Fern\u00e1ndez de Gatta Garcia","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jgar.2025.09.005_bib0016","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2025.09.005_bib0017","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ijantimicag.2014.05.011","article-title":"Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions","volume":"44","author":"Lip\u0161","year":"2014","journal-title":"Int J AntimicrobAgents"},{"key":"10.1016\/j.jgar.2025.09.005_bib0018","article-title":"Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials","volume":"22","author":"J","year":"2003","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"key":"10.1016\/j.jgar.2025.09.005_bib0019","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3390\/jcm8081211","article-title":"Nutrition in cancer patients","volume":"8","author":"Ravasco","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jgar.2025.09.005_bib0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1017\/S002966511500419X","article-title":"Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later","volume":"75","author":"Ryan","year":"2016","journal-title":"Proc Nutr Soc"},{"key":"10.1016\/j.jgar.2025.09.005_bib0021","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.chest.2023.07.009","article-title":"Optimizing vasopressin use and initiation timing in septic shock: A narrative review","volume":"164","author":"Sacha","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.jgar.2025.09.005_bib0022","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/cc6197","article-title":"Vasopressin in septic shock: effects on pancreatic, renal, and hepatic blood flow","volume":"11","author":"Krejci","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.jgar.2025.09.005_bib0023","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/phar.2597","article-title":"NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit","volume":"41","author":"Jaruratanasirikul","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2025.09.005_bib0024","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/ejhpharm-2022-003403","article-title":"Population pharmacokinetics and dosing optimisation of imipenem in critically ill patients","volume":"31","author":"Bai","year":"2024","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.jgar.2025.09.005_bib0025","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/WNL.0000000000002023","article-title":"Seizures as adverse events of antibiotic drugs: a systematic review","volume":"85","author":"Sutter","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jgar.2025.09.005_bib0026","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12882-024-03469-2","article-title":"Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy","volume":"25","author":"Lewis","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jgar.2025.09.005_bib0027","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijantimicag.2018.10.006","article-title":"Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy","volume":"53","author":"Li","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.09.005_bib0028","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jphs.2014.12.003","article-title":"Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia","volume":"127","author":"Jaruratanasirikul","year":"2015","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.jgar.2025.09.005_bib0029","first-page":"161","article-title":"SAMBA: A novel method for fast automatic model building in nonlinear mixed-effects models","volume":"11","author":"Prague","year":"2022","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"issue":"4","key":"10.1016\/j.jgar.2025.09.005_bib0030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4065\/74.4.420","article-title":"Carbapenems and monobactams: imipenem, meropenem, and aztreonam","volume":"74","author":"Hellinger","year":"1999","journal-title":"Mayo Clinic proceedings"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T22:02:43Z","timestamp":1780783363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525002073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"alternative-id":["S2213716525002073"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.09.005","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of imipenem in solid tumor patients with infections: A real-world study","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}